Abstract:Background: Diagnosis of dementia with Lewy bodies (DLB) is challenging, especially in the earlier stages of the disease, owing to the clinical overlap with other neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD). We aimed to identify the transcranial sonography (TCS) parameters that can help us to detect early DLB patients. Methods: In this cross-sectional study, we prospectively recruited newly diagnosed DLB patients with less than 3 years from the onset of cognitive symptoms. For comparison purposes, we also included AD and PD patients, with a disease duration of less than 3 years, and a control group. TCS was performed to assess the substantia nigra (SN) echogenicity, the width of the third ventricle, and the frontal horns of the lateral ventricles. Subsequently, TCS images were analyzed with the medical image viewer Horos in order to quantify the intensity of the echogenicity of the SN. Univariate analysis and a logistic regression model were used to identify which variables can predict the diagnosis of DLB. Results: One hundred and seven participants were included (23 DLB, 26 AD, 27 PD and 31 controls). The median age of DLB patients was 75(72-77) years, with a disease duration of 2 years. DLB and PD patients showed higher SN hyperechogenicity rates (72.73% and 81.82%, respectively) and a greater area of the SN compared to AD patients and controls (p < 0.001). DLB and AD patients had wider ventricular systems than the other study groups. The SN hyperechogenicity predicted a diagnosis of DLB with an odds ratio of 22.67 (95%CI 3.98; 129.12, p < 0.001) when compared to AD patients. Unilateral and bilateral widened frontal horns predicted diagnosis of DLB compared to PD with an odds ratio of 9.5 (95%CI 0.97; 92.83, p = 0.053) and 5.7 (95%CI 0.97; 33.6, p = 0.054), respectively. Conclusions: Echogenicity of the SN and widening of the frontal horns of lateral ventricles can predict the diagnosis of early DLB in this cohort of newly diagnosed patients, when compared to AD and PD patients. Transcranial sonography, a non-invasive tool, could be helpful for the diagnosis of DLB at its earlier stages.

Loss of the "swallow tail sign" on susceptibility-weighted imaging in the diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis

MRI Quantitative Susceptibility Mapping of the Substantia Nigra As an Early Biomarker for Lewy Body Disease.

Substantia nigra hyperechogenicity and brain ventricular size as biomarkers of early dementia with Lewy bodies

Utility of neuromelanin-sensitive MRI in the diagnosis of dementia with Lewy bodies

Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers

Relationships between neuroimaging biomarkers and glymphatic-system activity in dementia with Lewy bodies

Proton Magnetic Resonance Spectroscopy Detects A Relative Decrease of N-Acetylaspartate in the Hippocampus of Patients with Dementia with Lewy Bodies

Accuracy of transcranial brain parenchyma sonography in the diagnosis of dementia with Lewy bodies

Diagnostic Sensitivity and Symptomatic Relevance of Dopamine Transporter Imaging and Myocardial Sympathetic Scintigraphy in Patients with Dementia with Lewy Bodies

Neuroimaging alterations in dementia with Lewy bodies and neuroimaging differences between dementia with Lewy bodies and Alzheimer's disease: An activation likelihood estimation meta-analysis

CSF alpha-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies A Systematic Review and Meta-analysis

Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis

Comparative analysis of quantitative susceptibility mapping in preclinical dementia detection

Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts

Meta-analysis of Susceptibility-weighted Imaging in Diagnosis of Alzheimer's Disease

Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies

CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies

Myocardial Sympathetic Innervation Imaging with MIBG in Dementia with Lewy Bodies

High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases

Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings

Characteristics of Cortical Atrophy and White Matter Lesions Between Dementia With Lewy Bodies and Alzheimer's Disease: A Case-Control Study